SKB-571

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameSKB-571
Drug Alias NameSKB571SKB-571MK-2750
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A